Keros Therapeutics Inc. (KROS)
11.21
0.13 (1.17%)
At close: Mar 03, 2025, 12:39 PM
Keros Therapeutics Ratios Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| PE Ratio | -3.16 | -7.65 | -11.58 | -23.24 | -24.11 | -14.45 | -133.6 |
| PEG Ratio | 0.82 | -0.3 | -0.18 | 1.66 | -0.22 | -0.02 | n/a |
| PS Ratio | 166.94 | 7.75K | n/a | 67.92 | n/a | 17.84 | 17.84 |
| PB Ratio | 1.04 | 3.52 | 4.37 | 5.61 | 4.18 | 32.72 | 13.98 |
| P/FCF Ratio | -3.64 | -9.22 | -17 | -21.61 | -29.41 | -10.96 | 26.13 |
| P/OCF Ratio | -3.68 | -9.4 | -17.3 | -21.97 | -29.65 | -11.15 | 25.33 |
| OCF/S Ratio | -45.32 | -824.56 | n/a | -3.09 | n/a | -1.6 | 0.70 |
| Debt / Equity Ratio | 0.03 | 0.04 | 0.05 | 0.00 | 0.00 | 0.23 | 0.06 |
| Quick Ratio | 21.45 | 14.25 | 17.32 | 20.97 | 37.06 | 1.82 | 2.23 |
| Current Ratio | 21.45 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | 2.23 |
| Asset Turnover | 0.01 | 0.00 | n/a | 0.08 | n/a | 0.91 | 0.36 |
| Interest Coverage | n/a | n/a | -114.79K | -14.09K | -7.78K | -1.32K | n/a |
| Return on Equity (ROE) | -0.33 | -0.46 | -0.38 | -0.24 | -0.17 | -2.26 | -0.1 |
| Return on Assets (ROA) | -0.3 | -0.41 | -0.34 | -0.23 | -0.17 | -1.13 | -0.05 |
| Return on Capital (ROIC) | -0.36 | -0.49 | -0.4 | -0.23 | -0.18 | -1.63 | -0.11 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | 100.00% | -439.74% | n/a | 95.53% | n/a | -73.48% | -1.11% |
| Net Profit Margin | -5.28K% | -101.32K% | n/a | -292.26% | n/a | -123.44% | -13.35% |
| Pretax Profit Margin | -5.27K% | -101.32K% | n/a | -282.25% | n/a | -123.36% | -10.78% |
| Operating Profit Margin | -5.94K% | -112.54K% | n/a | -280.46% | n/a | -105.63% | -16.91% |
| FCF Margin | -4.59K% | -84.09K% | n/a | -314.29% | n/a | -162.69% | 68.25% |
| EBITDA Margin | -5.23K% | -100.78K% | n/a | -280.46% | n/a | -118.9% | -7.74% |